Page last updated: 2024-11-04

quinolinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1066
CHEMBL ID286204
CHEBI ID16675
SCHEMBL ID69230
MeSH IDM0026392

Synonyms (142)

Synonym
chembl286204 ,
pyridine carboxylate, 6c
bdbm26115
HMS3266C15
CHEBI:16675 ,
DIVK1C_000773
KBIO1_000773
AC-907/25014157
EU-0100989
2,3-pyridinedicarboxylic acid, 99%
SPECTRUM_001525
nsc 13127
einecs 201-874-8
nsc-18836
nsc18836
nsc-13127
nsc13127
tocris-0225
lopac-p63204
NCGC00015865-01
NCGC00024506-01
PDSP1_000133
OPREA1_139764
SPECTRUM5_001170
PDSP2_000132
LOPAC0_000989
BSPBIO_003143
nsc403247
nsc-403247
inchi=1/c7h5no4/c9-6(10)4-2-1-3-8-5(4)7(11)12/h1-3h,(h,9,10)(h,11,12
ai3-63017
2,3-pyridinedicarboxylic acid (8ci,9ci)
pyridine-2,3-carboxylate
STK365157
pyridine-2,3-dicarboxylate
pyridine-2,3-dicarboxylic acid
89-00-9
2,3-pyridinedicarboxylic acid ,
QUINOLINATE ,
2,3-pyridinedicarboxylate
C03722
quinolinic acid
DB01796
NCGC00024506-04
NCGC00024506-03
c7h5no4
KBIO2_002005
KBIO2_007141
KBIO3_002643
KBIOSS_002005
KBIO2_004573
KBIOGR_000711
NINDS_000773
SPBIO_000838
SPECTRUM2_000929
SPECTRUM3_001502
SPECTRUM4_000336
SPECTRUM1502102
IDI1_000773
NCGC00024506-06
NCGC00024506-05
NCGC00024506-02
MLS001332418
MLS002153210
MLS001332417
smr000112287
NCGC00015865-03
AC-11734
P63204
NCGC00015865-08
BMSE000219
HMS502G15
pyridin-2,3-dicarbonsaeure
P0550
HMS1921J12
AKOS000119760
HMS3263E19
hsdb 7511
ec 201-874-8
unii-f6f0hk1urn
f6f0hk1urn ,
BBL007601
cas-89-00-9
dtxcid6021327
NCGC00255468-01
dtxsid8041327 ,
tox21_302051
HMS2267B04
S3624
CCG-39677
NCGC00015865-04
NCGC00015865-07
NCGC00015865-06
NCGC00015865-02
NCGC00015865-05
FT-0674187
FT-0689818
FT-0609764
LP00989
28605-84-7
quinolinic acid [mi]
SCHEMBL69230
AM81291
FG-0461
pyridinedicarboxylic acid
pyridine-5,6-dicarboxylic acid
tox21_500989
NCGC00261674-01
Z57160166
339155-13-4
Q-201654
quin
CS-W020665
HB0544
MLS-0411909.P016
2,3-pyridine dicarboxylic acid
mfcd00006295
F2191-0231
MLS-0411909
2,3-pyridinedicarboxylic acid, vetec(tm) reagent grade, 98%
J-019373
SR-01000075472-3
sr-01000075472
SR-01000075472-1
HY-100807
SY003044
Q411945
HMS3675C05
HMS3411C05
2,3-dipicolinic acid
EN300-18090
SDCCGSBI-0050962.P003
HMS3885A17
NCGC00015865-12
quinolinic-acid
D70926
2-propenamide, n-[(3-fluorophenyl)methyl]-
SDCCGMLS-0411909.P028
2,3-pyridinedicarboxylic acid-d3
PB47350
pyridine-2,3-dicarboxylicacid
2,3-pyridinedicarboxylicacid, labeled with tritium (9ci)

Research Excerpts

Overview

Quinolinic acid (QA) is a pyridine derivative that can be found in many organisms and is widely used in the chemical industry. It is an N-methyl-D-aspartate receptor agonist, and raised levels in CSF, together with increased levels of inflammatory cytokines, have been reported in mood disorders.

ExcerptReferenceRelevance
"Quinolinic acid (QUIN) is an important agonist of NMDA receptors that are found at high levels in cases of brain injury and neuroinflammation. "( Quinolinic Acid Impairs Redox Homeostasis, Bioenergetic, and Cell Signaling in Rat Striatum Slices: Prevention by Coenzyme Q
Dos Santos, TM; Ferreira, FS; Ramires Junior, OV; Schmitz, F; Silveira, JS; Wyse, ATS, 2022
)
3.61
"Quinolinic acid (QA) is a pyridine derivative that can be found in many organisms and is widely used in the chemical industry. "( Biodegradation of quinolinic acid by a newly isolated bacterium Alcaligenes faecalis strain JQ191.
He, J; Hong, Q; Jiang, Y; Qiu, J; Wang, K; Zhang, X; Zhao, L; Zhao, Z, 2022
)
2.5
"Quinolinic acid is an N-methyl-D-aspartate receptor agonist, and raised levels in CSF, together with increased levels of inflammatory cytokines, have been reported in mood disorders."( The Role of Tryptophan Dysmetabolism and Quinolinic Acid in Depressive and Neurodegenerative Diseases.
Aaseth, JO; Alexander, J; Hestad, K; Rootwelt, H, 2022
)
1.71
"Quinolinic acid (QUIN) is an agonist of N-methyl-D-aspartate receptor (NMDAr) used to study the underlying mechanism of excitotoxicity in animal models. "( Quinolinic Acid Induces Alterations in Neuronal Subcellular Compartments, Blocks Autophagy Flux and Activates Necroptosis and Apoptosis in Rat Striatum.
Barrera-Oviedo, D; Hernández-Pando, R; León-Contreras, JC; Maldonado, PD; Pedraza-Chaverri, J; Santana-Martínez, RA; Silva-Islas, CA, 2022
)
3.61
"Quinolinic acid (QA) is an essential nitrogen-containing aromatic heterocyclic compounds in organisms and it also acts as an important intermediate in chemical industry, which has strong neurotoxicity and cytotoxicity. "( Quinolinic acid catabolism is initiated by a novel four-component hydroxylase QuiA in Alcaligenes faecalis JQ191.
Chen, E; He, J; Hu, G; Qiu, J; Wang, K; Yuan, C; Zhang, F; Zhang, X; Zhao, L, 2023
)
3.8
"Quinolinic acid (QUIN) is a toxic compound with pro-oxidant, pro-inflammatory, and pro-apoptotic actions found at high levels in the central nervous system (CNS) in several pathological conditions. "( Effect of Quinolinic Acid on Behavior, Morphology, and Expression of Inflammatory/oxidative Status in Rats' Striatum: Is Coenzyme Q
Alves, VS; Coutinho-Silva, R; Deniz, BF; Dos Santos, TM; Ferreira, FS; Junior, OVR; Savio, LEB; Silveira, JS; Wyse, ATS, 2023
)
2.76
"Quinolinic acid (QA) is a metabolite of the kynurenine pathway, which is activated by inflammatory stimuli during viral infection. "( The possible role of quinolinic acid as a predictive marker in patients with SARS-CoV-2.
Baranyi, A; Enko, D; Herrmann, M; Meinitzer, A; Michaelis, S; Schnedl, WJ; Schneider, C; Zelzer, S, 2023
)
2.67
"Quinolinic acid (QA) is a key intermediate of nicotinic acid (Niacin) which is an essential human nutrient and widely used in food and pharmaceutical industries. "( Metabolic engineering of Escherichia coli for quinolinic acid production by assembling L-aspartate oxidase and quinolinate synthase as an enzyme complex.
Bennett, GN; Peña, M; Zhu, F, 2021
)
2.32
"Quinolinic acid (QUIN) is an agonist of the neurotransmitter glutamate (Glu) capable of binding to N-methyl-D-aspartate receptors (NMDAR) increasing glutamatergic signaling. "( Caenorhabditis elegans as a model for studies on quinolinic acid-induced NMDAR-dependent glutamatergic disorders.
Antunes Soares, FA; Aschner, M; Bicca Obetine Baptista, F; Duarte Hartmann, D; Farina Gonçalves, D; Franzen da Silva, A; Lenz Dalla Corte, C; Limana da Silveira, T; Lopes Machado, M; Marafiga Cordeiro, L, 2021
)
2.32
"Quinolinic acid (QA) is a product of tryptophan degradation and its pathologic accumulation has been found to induce neuroinflammatory and demyelinating diseases such as multiple sclerosis via excessive free radicals generation. "( Terminalia chebula attenuates quinolinate-induced oxidative PC12 and OLN-93 cell death.
Afshari, AR; Forouzanfar, F; Jamshidi, R; Mollazadeh, H; Rakhshandeh, H; Sadeghnia, HR, 2017
)
1.9
"Quinolinic acid (QUIN) is an endogenous neurotoxin that acts as an N-methyl-D-aspartate receptor (NMDAR) agonist generating a toxic cascade, which can lead to neurodegeneration. "( Quinolinic acid and glutamatergic neurodegeneration in Caenorhabditis elegans.
Arantes, LP; Aschner, M; Câmara, DF; da Silva, TC; da Silveira, TL; Machado, ML; Santamaría, A; Soares, FAA; Zamberlan, DC, 2018
)
3.37
"Quinolinic acid (QUIN) is a well-known neuroactive metabolite of tryptophan degradation pathway or kynurenine pathway. "( Effect of wedelolactone and gallic acid on quinolinic acid-induced neurotoxicity and impaired motor function: significance to sporadic amyotrophic lateral sclerosis.
Goli, D; S, M; T, P, 2018
)
2.19
"Quinolinic acid (QUIN) is a neurotoxin, gliotoxin, and proinflammatory molecule involved in the pathogenesis of several neurological diseases. "( Neuroprotective Effect of Myxobacterial Extracts on Quinolinic Acid-Induced Toxicity in Primary Human Neurons.
Braidy, N; Dehhaghi, M; Guillemin, GJ; Heng, B; Mohammadipanah, F; Tan, V, 2019
)
2.21
"Quinolinic acid (QUIN) is an excitotoxic and pro-oxidant molecule used in the study of neurodegenerative disorders because it reproduces certain biochemical characteristics present in these diseases. "( Acute expression of the transcription factor Nrf2 after treatment with quinolinic acid is not induced by oxidative stress in the rat striatum.
Barrera-Oviedo, D; Chánez-Cárdenas, ME; Ibarra-Rubio, ME; Maldonado, PD; Silva-Islas, CA, 2019
)
2.19
"Quinolinic acid (QA) is an excitotoxic metabolite of the kynurenine pathway of tryptophan metabolism produced in response to inflammation and oxidative stress. "( Memantine Is Protective against Cytotoxicity Caused by Lead and Quinolinic Acid in Cultured Rat Embryonic Hippocampal Cells.
Al-Qenaie, S; Guillemin, GJ; Khan, KM; Rahman, A; Rao, MS, 2019
)
2.2
"Quinolinic acid is an intermediate in the kynurenine pathway."( Secretion of quinolinic acid, an intermediate in the kynurenine pathway, for utilization in NAD+ biosynthesis in the yeast Saccharomyces cerevisiae.
Kawai, S; Murata, K; Ohashi, K, 2013
)
1.48
"Quinolinic acid is a product of tryptophan degradation and may serve as a precursor for NAD(+), an important enzymatic cofactor for enzymes such as the DNA repair protein PARP. "( The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress.
Adams, S; Ahrendt, T; Bode, HB; Guillemin, GJ; Oezen, I; Opitz, CA; Platten, M; Radlwimmer, B; Sahm, F; von Deimling, A; Wick, W, 2013
)
2.08
"Quinolinic acid (QUIN) is a neurotoxic N-methyl-D-aspartate (NMDA) receptor agonist also produced by activated microglia/macrophages."( Microglia/macrophage-derived inflammatory mediators galectin-3 and quinolinic acid are elevated in cerebrospinal fluid from newborn infants after birth asphyxia.
Heyes, MP; Karlsson, A; Sävman, K; Svedin, P, 2013
)
1.35
"Quinolinic acid (QUIN) is a glutamate agonist which markedly enhances the vulnerability of neural cells to excitotoxicity. "( The phosphorylation status and cytoskeletal remodeling of striatal astrocytes treated with quinolinic acid.
Bincoletto, C; de Castro Medaglia, N; Ferreira, F; Gonçalves Fernandes, C; Ortiz de Lima, B; Pessoa-Pureur, R; Pierozan, P; Soubhi Smaili, S; Totarelli Monteforte, P, 2014
)
2.07
"Quinolinic acid (QUIN) is a neuroactive metabolite of the kinurenine pathway, and is considered to be involved in aging and some neurodegenerative disorders, including Huntington's disease. "( Biochemical, histopathological and behavioral alterations caused by intrastriatal administration of quinolic acid to young rats.
de Lima, BO; Dutra, MF; Fernandes, CG; Ferreira, F; Pandolfo, P; Pessoa-Pureur, R; Pierozan, P; Porciúncula, L; Wajner, M, 2014
)
1.85
"Quinolinic acid (QUIN) is an excitotoxin that has been implicated in the pathogenesis of several neurodegenerative diseases including Alzheimer's disease (AD). "( Changes in Cathepsin D and Beclin-1 mRNA and protein expression by the excitotoxin quinolinic acid in human astrocytes and neurons.
Braidy, N; Brew, BJ; Chung, R; Guillemin, GJ; Inestrosa, NC; Sachdev, P, 2014
)
2.07
"Quinolinic acid (QUIN) is a neuroactive metabolite of the kinurenine pathway, considered to be involved in aging and some neurodegenerative disorders, including Huntington׳s disease. "( Acute intrastriatal injection of quinolinic acid provokes long-lasting misregulation of the cytoskeleton in the striatum, cerebral cortex and hippocampus of young rats.
Ferreira, F; Gonçalves Fernandes, C; Pessoa-Pureur, R; Pierozan, P, 2014
)
2.13
"Quinolinic acid (QUIN) is an endogenous metabolite of the kynurenine pathway involved in several neurological disorders. "( Quinolinic acid induces disrupts cytoskeletal homeostasis in striatal neurons. Protective role of astrocyte-neuron interaction.
de Lima, BO; Ferreira, F; Pessoa-Pureur, R; Pierozan, P, 2015
)
3.3
"Quinolinic acid (QA) is a NMDA receptor agonist implicated in pathological conditions, such as neurodegenerative diseases and epilepsy. "( Cerebral cortex, hippocampus, striatum and cerebellum show differential susceptibility to quinolinic acid-induced oxidative stress.
Bertoldo, DB; De Bem, AF; Mancini, G; Martins, WC; Tasca, CI; Vandresen-Filho, S, 2015
)
2.08
"Quinolinic acid (QA) is an excitotoxin that induces Huntington's-like symptoms in animals and humans. "( Neuroprotective Activity of Curcumin in Combination with Piperine against Quinolinic Acid Induced Neurodegeneration in Rats.
Kumar, P; Singh, S, 2016
)
2.11
"Quinolinic acid (QA) is a neurotoxin that induces seizures when infused in vivo and promotes glutamatergic excitotoxicity in the central nervous system."( Atorvastatin Prevents Glutamate Uptake Reduction Induced by Quinolinic Acid Via MAPKs Signaling.
Bertoldo, DB; Leal, RB; Maestri, M; Martins, WC; Rieger, DK; Tasca, CI; Vandresen-Filho, S, 2016
)
1.4
"Quinolinic acid (QA) is a common intermediate in the biosynthesis of nicotinamide adenine dinucleotide (NAD(+)) and its derivatives in all organisms that synthesize the molecule de novo. "( Structure of Quinolinate Synthase from Pyrococcus horikoshii in the Presence of Its Product, Quinolinic Acid.
Booker, SJ; Esakova, OA; Grove, TL; McLaughlin, MI; Saunders, AH; Silakov, A; Yennawar, NH, 2016
)
2.1
"Quinolinic acid (QA) is a metabolite of tryptophan degradation obtained through kynurenine pathway, produced naturally in the mammalian brain as well as in the human cerebrospinal fluid. "( Excellent storage stability and sensitive detection of neurotoxin quinolinic acid.
Abraham, S; Gupta, TK; Kashyap, S; Kayastha, AM; Kumar, S; Malhotra, BD; Saxena, PS; Singh, R; Singh, RK; Srivastava, A, 2017
)
2.13
"Quinolinic acid (QA) is a well-known excitotoxic agent that could induce behavioral, morphological and biochemical alterations similar with symptoms of Huntington's disease (HD), by stimulating NMDA receptors."( Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status.
Kalonia, H; Kumar, A; Kumar, P; Nehru, B, 2009
)
1.31
"Quinolinic acid (QA) is an N-methyl-D-aspartate receptor agonist that also promotes glutamate release and inhibits glutamate uptake by astrocytes. "( Electrophysiological effects of guanosine and MK-801 in a quinolinic acid-induced seizure model.
Antoniolli, E; Antunes, C; da Silva Filho, M; Kalinine, E; Portela, LV; Souza, DO; Torres, FV; Tort, AB, 2010
)
2.05
"Quinolinic acid is an endogenous excitotoxin that causes neurotoxicity in diverse areas of the brain and produces motor dysfunction."( Protective effect of rofecoxib and nimesulide against intra-striatal quinolinic acid-induced behavioral, oxidative stress and mitochondrial dysfunctions in rats.
Kalonia, H; Kumar, A; Kumar, P; Nehru, B, 2010
)
1.32
"Quinolinic acid (QA) is an agonist NMDA receptors implicated in the neurobiology of seizures."( Intracerebroventricular administration of inosine is anticonvulsant against quinolinic acid-induced seizures in mice: an effect independent of benzodiazepine and adenosine receptors.
Almeida, RF; Faraco, RB; Fernandes, VF; Ganzella, M; Souza, DO, 2011
)
1.32
"Quinolinic acid (QuinA) is a tryptophan metabolite produced by activated macrophages."( Increased serum levels of quinolinic acid indicate enhanced severity of hepatic dysfunction in patients with liver cirrhosis.
Daniel, V; Elhadedy, H; Fusch, G; Iancu, M; Jung, G; Lahdou, I; Mehrabi, A; Opelz, G; Oweira, H; Sadeghi, M; Sandra-Petrescu, F; Schefold, JC; Schmidt, J; Terness, P, 2013
)
1.41
"Quinolinic acid is an agonist at N-methyl-D-aspartate receptors (NMDARs), but is also pro-oxidant, has immunomodulatory actions, and promotes the formation of hyperphosphorylated tau proteins."( An expanding range of targets for kynurenine metabolites of tryptophan.
Darlington, LG; Stone, TW; Stoy, N, 2013
)
1.11
"Quinolinic acid (QA) is a potent endogenous excitotoxin; elevation of its concentration in an organism has been implicated in the pathogenesis of various disorders. "( Contribution of quinolinic acid in the development of anemia in renal insufficiency.
Buczko, W; Koda, M; Pawlak, D; Pawlak, S; Wolczynski, S, 2003
)
2.11
"Quinolinic acid is an agonist at the population of glutamate receptors which are sensitive to N-methyl-D-aspartate (NMDA), and kynurenic acid is an antagonist at several glutamate receptors."( Tryptophan metabolites and brain disorders.
Clark, CJ; Darlington, LG; Forrest, CM; Mackay, GM; Stone, TW, 2003
)
1.04
"Quinolinic acid (QUIN) is a product of tryptophan metabolism that can act as an endogenous brain excitotoxin when released by activated macrophages. "( CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy.
Heyes, M; Nilsson, A; Price, RW; Valle, M; Verotta, D, 2004
)
2.32
"Quinolinic acid (QUIN) is an end product of tryptophan, metabolized through the kynurenine pathway (KP) that can act as an endogenous brain excitotoxin when produced and released by activated macrophages/microglia, the very cells that are prominent in the pathogenesis of ADC."( Involvement of quinolinic acid in AIDS dementia complex.
Brew, BJ; Guillemin, GJ; Kerr, SJ, 2005
)
1.4
"Quinolinic acid (QA) is a glutamatergic agent that induces seizures and is involved in the etiology of epilepsy."( In vivo quinolinic acid increases synaptosomal glutamate release in rats: reversal by guanosine.
Abud, J; Schmidt, AP; Souza, DO; Tasca, CI; Tavares, RG, 2005
)
1.48
"Quinolinic acid is a well-known excitotoxin that induces oxidative stress and damage. "( Melatonin neutralizes neurotoxicity induced by quinolinic acid in brain tissue culture.
Alvarez-García, O; Caballero, B; Coto-Montes, A; Poeggeler, B; Rodríguez-Colunga, MJ; Sierra-Sánchez, V; Tolivia, D; Tomás-Zapico, C; Vega-Naredo, I, 2005
)
2.03
"Quinolinic acid (QA) is an excitotoxin that, when injected in the rat striatum reproduces many features of HD and that acts by stimulating glutamate outflow."( The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum.
Calamandrei, G; Coccurello, R; Cuomo, V; Felici, F; Galluzzo, M; Grieco, R; Martire, A; Pèzzola, A; Pintor, A; Piomelli, D; Popoli, P; Scattoni, ML; Tebano, MT, 2006
)
1.28
"Quinolinic acid (QA) is an endogenous excitotoxin acting on N-methyl-d-aspartate receptors (NMDARs) that leads to the pathologic and neurochemical features similar to those observed in Huntington's disease (HD). "( L-NAME reverses quinolinic acid-induced toxicity in rat corticostriatal slices: Involvement of src family kinases.
Di Stasi, AM; Domenici, MR; Mallozzi, C; Martire, A; Metere, A; Popoli, P, 2007
)
2.13
"Quinolinic acid is an agonist at glutamate receptors sensitive to N-methyl-D-aspartate (NMDA). "( Interleukin-1beta but not tumor necrosis factor-alpha potentiates neuronal damage by quinolinic acid: protection by an adenosine A2A receptor antagonist.
Behan, WM; Stone, TW, 2007
)
2.01
"Quinolinic acid (QA) is an endogenous glutamate analog that may be involved in the etiology of epilepsy and is related to disturbances on glutamate release and uptake."( Quinolinic acid-induced seizures stimulate glutamate uptake into synaptic vesicles from rat brain: effects prevented by guanine-based purines.
Schmidt, AP; Souza, DO; Tasca, CI; Tavares, RG, 2008
)
2.51
"Quinolinic acid (QUIN) is an endogenous, excitotoxic amino acid which is currently under investigation as a possible etiological factor in human neurodegenerative disorders such as Huntington's disease and epilepsy. "( Studies on the disposition of quinolinic acid after intracerebral or systemic administration in the rat.
Foster, AC; Miller, LP; Oldendorf, WH; Schwarcz, R, 1984
)
2
"Quinolinic acid (QUIN) is an excitotoxic tryptophan metabolite that is produced by activated macrophages. "( Quinolinic acid accumulation and functional deficits following experimental spinal cord injury.
Blight, AR; Cohen, TI; Heyes, MP; Saito, K, 1995
)
3.18
"Quinolinic acid is an excitatory, neurotoxic tryptophan metabolite proposed to play a role in the pathogenesis of hepatic encephalopathy. "( The relationship between plasma and brain quinolinic acid levels and the severity of hepatic encephalopathy in animal models of fulminant hepatic failure.
Basile, AS; Heyes, MP; Li, Y; Saito, K, 1995
)
2
"Quinolinic acid (QUIN) is a neurotoxin and endogenous N-methyl-D-aspartate receptor agonist formed from tryptophan."( Neurotoxin quinolinic acid is selectively elevated in spinal cords of rats with experimental allergic encephalomyelitis.
Chang, SY; Erickson, JB; Flanagan, EM; Reinhard, JF; Viveros, OH, 1995
)
1.4
"Quinolinic acid is an endogenous neuroexcitant derived from tryptophan. "( The relationship between plasma and brain quinolinic acid levels and the severity of hepatic encephalopathy.
al-Mardini, H; Basile, AS; Harrison, P; Heyes, MP; Hughes, RD; Li, Y; Record, CO; Saito, K; Williams, R, 1995
)
2
"Quinolinic acid (QUIN) is a potential pathogen in a variety of excitotoxic and neuroviral brain diseases. "( 4-Chloro-3-hydroxyanthranilate inhibits quinolinate production in the rat hippocampus in vivo.
Schwarcz, R; Ungerstedt, U; Walsh, JL; Wu, HQ, 1994
)
1.73
"Quinolinic acid (QUIN) is a neurotoxin implicated in the neurologic deficits associated with human immunodeficiency virus type 1 (HIV-1) infection. "( Quinolinic acid in the cerebrospinal fluid of children with symptomatic human immunodeficiency virus type 1 disease: relationships to clinical status and therapeutic response.
Brouwers, P; Heyes, MP; Markey, SP; Moss, HA; Pizzo, PA; Poplack, DG; Wolters, PL, 1993
)
3.17
"Quinolinic acid (QUIN) is an endogenous metabolite that exerts a neurotoxic effect by binding to specific neuronal receptors. "( Sensorineural hearing loss from quinolinic acid: a neurotoxin in middle ear effusions.
Casselbrant, M; Diven, WF; Doyle, WJ; Heyes, MP; Kenna, MA; Rose, E; Swarts, JD; Whiteside, TL; Yellon, RF, 1994
)
2.01
"Quinolinic acid (QUIN) is an endogenous neurotoxic N-methyl-D-aspartate agonist that may contribute to the pathogenesis of HIV-associated neurologic disease."( Quinolinic acid levels in a murine retrovirus-induced immunodeficiency syndrome.
Hartley, JW; Heyes, MP; Layar, R; Morse, HC; Paul, IA; Saito, K; Sei, Y; Skolnick, P, 1996
)
2.46
"Quinolinic acid (QUIN) is a neurotoxic metabolite of the kynurenine pathway that accumulates within the central nervous system following immune activation."( Quinolinic acid in tumors, hemorrhage and bacterial infections of the central nervous system in children.
Heyes, MP; Milstien, S; Saito, K; Schiff, SJ, 1995
)
2.46
"Quinolinic acid is an endogenous neurotoxin with NMDA receptor agonist properties. "( The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits.
Bochet, P; de Carvalho, LP; Rossier, J, 1996
)
2.05
"Quinolinic acid (QA) is a neurotoxin and has been shown to be present at high levels in the central nervous system of patients with certain diseases, such as AIDS and meningitis. "( A new function for a common fold: the crystal structure of quinolinic acid phosphoribosyltransferase.
Eads, JC; Grubmeyer, C; Ozturk, D; Sacchettini, JC; Wexler, TB, 1997
)
1.98
"Quinolinic acid (QUIN) is a tryptophan metabolite which has been found to be an excitotoxin in rats, although its toxicity in humans is unknown. "( Neurocytotoxity of quinolinic acid in human brain cultures.
Armati, PJ; Brew, BJ; Kerr, SJ, 1995
)
2.06
"Quinolinic acid is an excitotoxic kynurenine pathway metabolite, the concentration of which increases in human brain during immune activation. "( Species heterogeneity between gerbils and rats: quinolinate production by microglia and astrocytes and accumulations in response to ischemic brain injury and systemic immune activation.
Beagles, KE; Chen, CY; Heyes, MP; Kawai, K; Li, J; Markey, SP; Nowak, TS; Proescholdt, MA; Proescholdt, MG; Saito, K; Zito, MA, 1997
)
1.74
"Quinolinic acid (QUIN) is a neurotoxic tryptophan metabolite produced by macrophages in response to stimulation with cytokines or infection with HIV-1."( Kynurenine pathway inhibition reduces neurotoxicity of HIV-1-infected macrophages.
Armati, PJ; Brew, BJ; Kerr, SJ; Pemberton, LA; Smythe, G; Tattam, B, 1997
)
1.02
"Quinolinic acid (QUIN) is an endogenous excitotoxic agonist of the N-methyl-D-aspartate (NMDA) type of glutamate receptor, which causes slowly progressing degeneration of vulnerable neurons in some brain regions. "( Biochemical characteristics of gamma-glutamyl transpeptidase in capillaries from entorhinohippocampal complex of quinolinate-lesioned rat brain.
Dvoráková, L; Lisý, V; Stastný, F,
)
1.57
"Quinolinic acid (QUIN) is an endogenous excitatory amino acid, which is elevated in brain tissues or cerebrospinal fluid (CSF) in several acute and chronic inflammatory central nervous system (CNS) diseases. "( Neurochemical and metabolic consequences of elevated cerebrospinal fluid quinolinic acid concentrations in rat brain.
Kaneda, H; Maeda, K; Tamminga, CA; Whetsell, WO, 1997
)
1.97
"Quinolinic acid (QUIN) is an endogenous neurotoxin which originates from the kynurenine pathway of tryptophan metabolism. "( Temporal and spatial changes of quinolinic acid immunoreactivity in the gerbil hippocampus following transient cerebral ischemia.
Barattè, S; Benatti, L; Molinari, A; Salvati, P; Speciale, C; Veneroni, O, 1998
)
2.03
"Quinolinic acid (QUIN) is an endogenous excitotoxin acting on N-methyl-D-aspartate (NMDA) receptors, that leads to neurotoxic damage resembling the alterations observed in Huntington's disease. "( Nitric oxide synthase inhibition prevents acute quinolinate-induced striatal neurotoxicity.
Escalante, B; Pérez-Severiano, F; Ríos, C, 1998
)
1.74
"Quinolinic acid is a neurotoxic tryptophan metabolite produced locally during immune activation. "( Depletion of systemic macrophages by liposome-encapsulated clodronate attenuates increases in brain quinolinic acid during CNS-localized and systemic immune activation.
Heyes, MP; Koennecke, LA; Proescholdt, MG; van Rooijen, N; Zito, MA, 1999
)
1.96
"Quinolinic acid (QA) is an endogenous and potent neurotoxin associated with the neurotoxicity of various common diseases. "( Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain.
Dutra-Filho, CS; Santos, CE; Souza, DO; Tasca, CI; Tavares, RG; Wajner, M, 2000
)
3.19
"Quinolinic acid (QA) is an N-methyl-d-aspartate agonist that has been shown to produce neurotoxic effects that mimic certain neurodegenerative diseases when administered to laboratory animals. "( Quinolinic acid released from polymeric brain implants causes behavioral and neuroanatomical alterations in a rodent model of Huntington's disease.
Dunbar, GL; Haik, KL; Sabel, BA; Schroeder, U; Shear, DA, 2000
)
3.19
"Quinolinic acid is an agonist at the N-methyl-D-aspartate sensitive subtype of glutamate receptors in the brain, while kynurenic acid is an antagonist and, thus, a potential neuroprotectant."( Endogenous neurotoxins from tryptophan.
Stone, TW, 2001
)
1.03
"Quinolinic acid (QA) is an endogenous neurotoxin involved in various neurological diseases, whose action seems to be exerted via glutamatergic receptors. "( Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes.
Alves, LB; Emanuelli, T; Porciúncula, LO; Santos, CE; Souza, DO; Tasca, CI; Tavares, RG, 2002
)
3.2
"Quinolinic acid is a natural metabolite of tryptophan, normally occurring in the liver, kidney and brain (Wolfensberger et al."( Quinolinic acid: effects on brain catecholamine and c-AMP content during L-dopa and reserpine administration.
Beskid, M; Finkiewicz-Murawiejska, L, 1992
)
2.45
"Quinolinic acid (QUIN) is an neurotoxic N-methyl-D-aspartate receptor agonist and an L-tryptophan metabolite of the kynurenine pathway. "( Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients.
Bhalla, RB; Brew, BJ; Der, M; Heyes, MP; Lee, K; Markey, SP; Price, RW; Quearry, BJ; Saito, K, 1992
)
2.02
"Quinolinic acid (QUIN) is an endogenous N-methyl-D-aspartate receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction."( Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
Crowley, JS; Davis, LE; Demitrack, MA; Der, M; Dilling, LA; Elia, J; Heyes, MP; Kruesi, MJ; Lackner, A; Saito, K, 1992
)
2.45
"Quinolinic acid (QUIN) is a neurotoxin and convulsant when injected directly into the brains of experimental animals and as such has been implicated in the etiology of human seizure disorders. "( Quinolinic acid concentrations in brain and cerebrospinal fluid of patients with intractable complex partial seizures.
Devinsky, O; Heyes, MP; Markey, SP; Nadi, NS; Wyler, AR; Yergey, JA,
)
3.02
"Quinolinic acid is an "excitotoxic" metabolite and an agonist of N-methyl-D-aspartate receptors. "( Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status.
Brew, BJ; Heyes, MP; Keilp, J; Martin, A; Mouradian, MM; Price, RW; Sadler, AE; Salazar, AM; Sidtis, JJ; Yergey, JA, 1991
)
3.17
"Quinolinic acid (QA) is an endogenous excitotoxin present in mammalian brain that reproduces many of the histologic and neurochemical features of Huntington's disease (HD). "( Systemic approaches to modifying quinolinic acid striatal lesions in rats.
Beal, MF; Ferrante, RJ; Kowall, NW; Martin, JB; Swartz, KJ, 1988
)
2
"Quinolinic acid is a potent neurotoxin and convulsant when it is injected into the central nervous system of experimental animals."( Hypothesis: a role for quinolinic acid in the neuropathology of glutaric aciduria type I.
Heyes, MP, 1987
)
1.3

Effects

Quinolinic acid has been reported to induce excitotoxicity by stimulating the N-methyl-D-aspartate receptor, causing calcium overload which in turn leads to the neurodegeneration. Quinolinic Acid (QA) has been used as a model for experimental overstimulation of the glutamatergic system.

ExcerptReferenceRelevance
"Quinolinic acid (QUIN) has been suggested to be involved in infections, inflammatory neurological disorders and in the development of psychiatric disorders. "( Quinolinic acid-immunoreactivity in the naïve mouse brain.
Kenis, G; Lopez, YP; Myint, AM; Rutten, BP; Steinbusch, HW; van den Hove, DL, 2016
)
3.32
"Quinolinic acid has been reported to induce excitotoxicity by stimulating the N-methyl-D-aspartate receptor, causing calcium overload which in turn leads to the neurodegeneration."( Protective effect of montelukast against quinolinic acid/malonic acid induced neurotoxicity: possible behavioral, biochemical, mitochondrial and tumor necrosis factor-α level alterations in rats.
Kalonia, H; Kumar, A; Kumar, P; Nehru, B, 2010
)
1.35
"Quinolinic acid (QA) has been used as a model for experimental overstimulation of the glutamatergic system. "( Quinolinic acid promotes seizures and decreases glutamate uptake in young rats: reversal by orally administered guanosine.
de Oliveira, DL; Frizzo, ME; Horn, JF; Moriguchi, E; Rodrigues, JM; Souza, DO; Wofchuk, S, 2004
)
3.21
"Quinolinic acid (QA) has been shown to evoke neurotoxic events via NMDA receptor (NMDAR) overactivation and oxidative stress. "( Quinolinic acid modulates the activity of src family kinases in rat striatum: in vivo and in vitro studies.
Di Stasi, AM; Domenici, MR; Mallozzi, C; Metere, A; Minetti, M; Pèzzola, A; Popoli, P, 2006
)
3.22
"Quinolinic acid (QUIN) has been associated with several inflammatory neurologic disorders, including AIDS dementia complex (ADC). "( Quinolinic acid production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha.
Brew, BJ; Kerr, SJ; Pemberton, LA; Smythe, G, 1997
)
3.18

Actions

Quinolinic acid was found to produce the convulsive discharges in the EEG 30-60 sec after administration. It activated all subunit combinations but was less efficient than NMDA only in the NR1 + NR2C subunit combination.

ExcerptReferenceRelevance
"Quinolinic acid did not activate receptors containing NR1 + NR2C but did activate receptors containing NR1 + NR2A and NR1 + NR2B even if only at millimolar concentrations; homoquinolinic acid activated all subunit combinations but was less efficient than NMDA only in the NR1 + NR2C subunit combination."( The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits.
Bochet, P; de Carvalho, LP; Rossier, J, 1996
)
1.33
"Quinolinic acid was found to produce the convulsive discharges in the EEG 30-60 sec after administration."( [Electroencephalographic manifestations of the convulsive reaction of rats to the intraventricular administration of quinolinic acid and kynurenine].
Kozlovskiĭ, VB; Prakh'e, IV,
)
1.06

Toxicity

Copper and manganese are two essential metals involved in physiological and physiopathological processes in the brain. The tryptophan metabolite quinolinic acid (QUIN) acts as an excitotoxin when its brain concentrations reach toxic levels under pathological conditions. KYNA antagonizes the toxic action of QUIN, an endogenous NMDA receptor agonist.

ExcerptReferenceRelevance
" The antagonistic properties of kynurenate were dose-dependent: equimolar kynurenate had no effect on quinolinate but attenuated the actions of ibotenate, kainate and NMDA; 2 x equimolar kynurenate had no effect on quinolinate or ibotenate but attenuated the toxicity of kainate and NMDA; and 3 x equimolar kynurenate had no effect on the toxicity of kainate or ibotenate, attenuated the actions of NMDA and abolished the toxic action of quinolinate."( A comparison of excitotoxic lesions of the basal forebrain by kainate, quinolinate, ibotenate, N-methyl-D-aspartate or quisqualate, and the effects on toxicity of 2-amino-5-phosphonovaleric acid and kynurenic acid in the rat.
Clark, AJ; Hastings, MH; Latimer, M; Stone, TW; Winn, P, 1991
)
0.28
" The effects of EAA co-incubation with the N-methyl-D-aspartate (NMDA) receptor antagonist, 2-amino-5-phosphonovaleric acid, suggested that the toxic actions of quinolinate, but not kainate, were mediated largely by NMDA receptors."( Quinolinate and kainate neurotoxicity in neostriatal cultures is potentiated by co-culturing with neocortical neurons.
Galarraga, E; Kitai, ST; Surmeier, DJ, 1990
)
0.28
" Morphological criteria were used to determine the toxic effects of glutamate in 6-, 12-, and 18-day-old cultures which were examined before and after 1-3 h of exposure to glutamate."( Characterization and mechanism of glutamate neurotoxicity in primary striatal cultures.
Beal, MF; DiFiglia, M; Freese, A; Koroshetz, WJ; Martin, JB, 1990
)
0.28
" It is concluded that some of the protein binding inhibitors have toxic effects on cell function of various tissues and play a role in pathophysiology of uremia."( [Study on the uremic protein binding inhibitors as uremic toxin: toxic effect on erythroid colony formation, lymphocyte blast formation and renal function].
Kawashima, Y, 1989
)
0.28
" DX also antagonized morphological and chemical (lactate dehydrogenase efflux) evidence of cortical neuronal cell injury produced by toxic bath exposure to NMDA, quinolinate or glutamate, but did not affect toxic exposure to quisqualate or kainate."( Dextrorphan and levorphanol selectively block N-methyl-D-aspartate receptor-mediated neurotoxicity on cortical neurons.
Choi, DW; Peters, S; Viseskul, V, 1987
)
0.27
" KYNA antagonizes the toxic action of quinolinic acid (QUIN), an endogenous NMDA receptor agonist."( Systemic DL-kynurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats.
Altagracia, M; González-Reynoso, L; Kravzov, J; Ordaz-Moreno, J; Ríos, C; Santamaría, A; Solís-Hernández, F, 1996
)
0.81
"Copper and manganese, two essential metals involved in physiological and physiopathological processes in the brain, were measured in corpora striata of rats 7 days after intrastriatal injection of quinolinic acid (QUIN, 240 nmol/l microliters), an N-methyl-D-aspartate (NMDA) receptor agonist with toxic activity."( Quinolinic acid neurotoxicity: in vivo increased copper and manganese content in rat corpus striatum after quinolinate intrastriatal injection.
Flores, A; Galván-Arzate, S; Osorio-Rico, L; Pérez, P; Ríos, C; Santamaría, A; Solís, F, 1996
)
1.93
" We observed that, while a decrease in total cell number produced by QUIN was not prevented by SP treatment, AChE-positive cells were rescued from the toxic damage."( Tachykinins protect cholinergic neurons from quinolinic acid excitotoxicity in striatal cultures.
Alberch, J; Calvo, N; Pérez-Navarro, E; Reiriz, J, 1996
)
0.55
"D-myo-Inositol hexakisphosphate (InsP6, phytate), a normal cellular constituent, was found to be toxic to neuronal perikarya when injected into the rat hippocampus."( Neuronal cytotoxicity of inositol hexakisphosphate (phytate) in the rat hippocampus.
Lees, GJ; Leong, W, 1996
)
0.29
" Oxidative stress was also measured both as lipid peroxidation and as the levels of reduced (GSH) and oxidized (GSSG) glutathione, in an effort to elucidate a possible participation of NO in the toxic mechanisms involved in NMDA receptor-mediated neuronal injury."( Nomega-nitro-L-arginine, a nitric oxide synthase inhibitor, antagonizes quinolinic acid-induced neurotoxicity and oxidative stress in rat striatal slices.
Espinoza-González, V; Ríos, C; Santamaría, A; Santamaría, D, 1999
)
0.54
" In contrast, neither QA up to 5 mM nor trans-ACPD had a significant toxic effect in either KCl group."( NMDA and non-NMDA receptor-mediated excitotoxicity are potentiated in cultured striatal neurons by prior chronic depolarization.
Chen, Q; Reiner, A; Surmeier, DJ, 1999
)
0.3
" All three acids were neurotoxic in a dose-dependent manner; however, GA and 3GA were both more toxic than QUIN."( IGF-1 and bFGF reduce glutaric acid and 3-hydroxyglutaric acid toxicity in striatal cultures.
Bjugstad, KB; Freed, CR; Goodman, S; Zawada, WM, 2001
)
0.31
" Moreover, the administration of MK-801 to rats as a pretreatment resulted in a complete prevention of the QUIN-induced NAD(P)H activation, suggesting that this toxic event is completely dependent on N-methyl-D-aspartate receptor overactivation."( NAD(P)H oxidase contributes to neurotoxicity in an excitotoxic/prooxidant model of Huntington's disease in rats: protective role of apocynin.
Galván-Arzate, S; Maldonado, PD; Molina-Jijón, E; Pedraza-Chaverrí, J; Santamaría, A; Villeda-Hernández, J, 2010
)
0.36
" The characterization of toxic cascades produced by QUIN during the first hours after its striatal infusion is relevant for understanding toxic mechanisms."( On the early toxic effect of quinolinic acid: involvement of RAGE.
Ali, SF; Cuevas, E; Divine, B; Lantz, S; Newport, G; Paule, MG; Santamaría, A; Tobón-Velasco, JC; Wu, Q, 2010
)
0.65
" Proteases activation is responsible for triggering deadly cascades during cell damage in toxic models."( Time-course correlation of early toxic events in three models of striatal damage: modulation by proteases inhibition.
Ali, SF; Carrillo-Mora, P; Chánez-Cárdenas, ME; Elinos-Calderón, D; Konigsberg, M; Morán, J; Pérez-De La Cruz, G; Pérez-De La Cruz, V; Santamaría, A; Silva-Adaya, D,
)
0.13
" Our data suggest that the two studied toxic models (QA and 3-NP) or the combined model (QA plus 3-NP) can generate complex patterns of damage, which involve metabolic compromise, ROS formation, and oxidative stress."( Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro.
Colle, D; Farina, M; Hartwig, JM; Soares, FA, 2012
)
0.38
" These findings support a neuroprotective and modulatory role of cannabinoids in the early toxic events elicited by agents inducing excitotoxic processes."( Cannabinoid receptor agonists reduce the short-term mitochondrial dysfunction and oxidative stress linked to excitotoxicity in the rat brain.
Castellanos, P; Colín-González, AL; Paz-Loyola, AL; Pinzón, E; Rangel-López, E; Santamaría, A; Serratos, IN; Souza, DO; Torres, I; Wajner, M, 2015
)
0.42
" This abnormal proteolysis leads to the accumulation of cleaved fragments, which have been identified as toxic and further they act as a seed for more aggregate formation, thereby increasing toxicity in neuronal cells."( n-Butylidenephthalide exhibits protection against neurotoxicity through regulation of tryptophan 2, 3 dioxygenase in spinocerebellar ataxia type 3.
Chiang, IT; Chiou, TW; Harn, HJ; Hsieh, DK; Lin, SY; Lin, SZ; Liu, JW; Rajamani, K; Wu, CH; You, DH, 2017
)
0.46
" However, their toxic properties have yet to be explored in the nematode Caenorhabditis elegans (C."( Comparison of the Toxic Effects of Quinolinic Acid and 3-Nitropropionic Acid in C. elegans: Involvement of the SKN-1 Pathway.
Aguilera-González, MF; Aschner, M; Avila, DS; Colonnello, A; de Lima, ME; García-Contreras, R; Kotlar, I; Ortíz-Plata, A; Santamaría, A; Soares, FAA, 2018
)
0.76
" The tryptophan metabolite quinolinic acid (QUIN) acts as an excitotoxin when its brain concentrations reach toxic levels under pathological conditions."( The Antiepileptic Drug Levetiracetam Protects Against Quinolinic Acid-Induced Toxicity in the Rat Striatum.
Aguilera, G; Colín-González, AL; Dircio-Bautista, M; Galván-Arzate, S; García, E; Maya-López, M; Santamaría, A; Túnez, I; Villeda-Hernández, J, 2018
)
1.03
" However, their single actions cannot explain the extent of brain damage observed in this disorder, and the characterization of co-adjuvant involved in the early toxic processes evoked in AD is essential."( Synergistic Toxicity of the Neurometabolites Quinolinic Acid and Homocysteine in Cortical Neurons and Astrocytes: Implications in Alzheimer's Disease.
Biasibetti-Brendler, H; Ferreira, F; Netto, CA; Pierozan, P; Schmitz, F; Wyse, ATS, 2018
)
0.74
" The QUIN is involved in the development of several toxic cascades which leads to the neuronal degeneration processes."( Effect of wedelolactone and gallic acid on quinolinic acid-induced neurotoxicity and impaired motor function: significance to sporadic amyotrophic lateral sclerosis.
Goli, D; S, M; T, P, 2018
)
0.74

Bioavailability

ExcerptReferenceRelevance
" Our results suggest that QUIN levels and function in the mammalian brain might be tightly controlled by endogenous iron and proteins that regulate the bioavailability of iron."( Regulation of quinolinic acid neosynthesis in mouse, rat and human brain by iron and iron chelators in vitro.
Schwarcz, R; Stachowski, EK, 2012
)
0.74
" This stimulation induces indoleamine 2,3-dioxygenase (IDO), an enzyme that reduces the tryptophan bioavailability to synthesize serotonin."( Chronic Mild Stress Alters Kynurenine Pathways Changing the Glutamate Neurotransmission in Frontal Cortex of Rats.
Caso, JR; García-Bueno, B; Leza, JC; Madrigal, JLM; Martín-Hernández, D; Tendilla-Beltrán, H, 2019
)
0.51
" It involves multiple pathways including interference with the bioavailability of tryptophan central to the synthesis of the neurotransmitter serotonin."( Role of Kynurenine pathway and its metabolites in mood disorders: A systematic review and meta-analysis of clinical studies.
Arnone, D; Dantzer, R; Salem, H; Saraykar, S; Selvaraj, S; Teixeira, AL, 2018
)
0.48
" Bioavailability of tryptophan is an absolute requirement for proper cell functioning and synthesis of hormones, whereas its degradation products can cause cell death."( Indoleamine 2,3-dioxygenase (IDO)-1 and IDO-2 activity and severe course of COVID-19.
Bugiani, M; Dijkhuis, A; Duitman, JW; Geeraerts, Z; Guo, L; Lutter, R; Nossent, EJ; Roos, E; Schurink, B; van der Valk, P; van Vught, L; Vaz, FM; Vlaar, AP; Yeh, SR, 2022
)
0.72
"Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach."( Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk, A; Urbanska, EM, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" Dose-response relationships, examination of brain regions distant from the two injection sites and the temporal sequence of the changes described here suggest a close association between QUIN-induced neuronal degeneration and alterations in the serotonergic system."( Effects of intracerebral injections of quinolinic acid on serotonergic neurons in the rat brain.
Aldinio, C; Köhler, C; Mazzari, S; Schwarcz, R; Toffano, G, 1985
)
0.54
" In the present study we examined dose-response effects of excitotoxins acting at the three subtypes of glutamate receptors: N-methyl-D-aspartate (AA1), quisqualate (AA2), and kainic acid (AA3)."( Differential sparing of somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions.
Beal, MF; Ferrante, RJ; Kowall, NW; Martin, JB; Swartz, KJ, 1989
)
0.28
" Dose-response relationships and the temporal sequence of this effect indicated a close functional association between seizure events and the decrease in hippocampal norepinephrine content."( A noradrenergic component of quinolinic acid-induced seizures.
Schwarcz, R; Vezzani, A, 1985
)
0.56
" Dose-response curves to the two compounds appeared parallel but NMDA was 30-fold more potent than QUIN."( Quinolinate mimics neurotoxic actions of N-methyl-D-aspartate in rat cerebellar slices.
Garthwaite, G; Garthwaite, J, 1987
)
0.27
" Dose-response curves and IC50 values were determined for these antagonists against all four agonists."( The action of quinolinate in the rat spinal cord in vitro.
Curry, K; Magnuson, DS; McLennan, H; Peet, MJ, 1987
)
0.27
" Dose-response relationships showed a close association between seizure activity (measured by EEG) and extracellular Ca2+ changes in the injected area."( Quinolinic acid-induced seizures, but not nerve cell death, are associated with extracellular Ca2+ decrease assessed in the hippocampus by brain dialysis.
Angelico, P; Samanin, R; Stasi, MA; Vezzani, A; Wu, HQ, 1988
)
1.72
" Ketamine, an NMDA-receptor antagonist prevented completely the QUIN-induced hippocampal damage at a dosage of 40 mg/kg (140 mumol/kg, intraperitoneally applied)."( Ketamine, but not glycine modulates quinolinate-induced neurodegeneration.
Henschke, G; Keilhoff, G; Wolf, G,
)
0.13
" Lesioned rats showed a cocaine dose-response function that was shifted upwards relative to control subjects."( Excitotoxic lesions of the basolateral amygdala impair the acquisition of cocaine-seeking behaviour under a second-order schedule of reinforcement.
Everitt, BJ; Markou, A; Robbins, TW; Whitelaw, RB, 1996
)
0.29
" Enzyme dosage ranged from 120 to 480 U/kg of body weight/month."( Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease.
Aerts, JM; Barton, NW; Brady, RO; Dambrosia, JM; DeGraba, T; Heyes, MP; Oliver, K; Parker, CC; Patterson, MC; Schiffmann, R; Tedeschi, G; Zirzow, GC, 1997
)
0.3
" After sham-lesioned rats reached a stable baseline, a between-sessions heroin dose-response function was established."( The effects of excitotoxic lesions of the nucleus accumbens core or shell regions on intravenous heroin self-administration in rats.
Alderson, HL; Everitt, BJ; Parkinson, JA; Robbins, TW, 2001
)
0.31
"Rats with lesions of the NAcc shell did not differ significantly from sham controls in either the acquisition of heroin self-administration or in their heroin dose-response function."( The effects of excitotoxic lesions of the nucleus accumbens core or shell regions on intravenous heroin self-administration in rats.
Alderson, HL; Everitt, BJ; Parkinson, JA; Robbins, TW, 2001
)
0.31
" These results establish the proof of principle of neurotrophic factor dosing for neurodegenerative diseases and demonstrate the feasibility of lentiviral-mediated tetracycline-regulated gene transfer in the brain."( Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease.
Aebischer, P; Déglon, N; Pereira de Almeida, L; Régulier, E; Sommer, B, 2002
)
0.52
" A lower pyruvate concentration of 250 mg/kg was not protective; however, quadruple applications at this dosage was effective in reducing lesion volumes."( Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease.
Kim, SU; McLarnon, JG; Ryu, JK, 2003
)
0.58
" The injection coordinates and the dosage of quinolinic acid were identical."( Ketamine anaesthesia interferes with the quinolinic acid-induced lesion in a rat model of Huntington's disease.
Büchele, F; Döbrössy, M; Jiang, W; Nikkhah, G; Papazoglou, A, 2009
)
0.88
" However, the administration system and the control over the dosage are still important problems to be solved."( BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease.
Alberch, J; Blanco, J; Canals, JM; Caneda-Ferrón, B; Friedman, HC; Giralt, A; Moreno, E; Peterson, A; Rubio, N; Urbán, N, 2010
)
0.36
" In the H2O2/FeCl3/ascorbic acid variant of the deoxyribose degradation assay, the dose-response curve was U-shaped."( Quinolinic acid: neurotoxin or oxidative stress modulator?
Chobot, V; Hadacek, F; Kubicova, L, 2013
)
1.83
"Lesions of the ventromedial prefrontal cortex induced impulsive deficits, and repeated milnacipran ameliorated the impulsive deficit both during the dosing period and after the cessation of the drug."( Milnacipran remediates impulsive deficits in rats with lesions of the ventromedial prefrontal cortex.
Izumi, T; Ohmura, Y; Tsutsui-Kimura, I; Yoshida, T; Yoshioka, M, 2014
)
0.4
" However, using a comprehensive panel of behavioral tests, we demonstrate that the chronic dosing of a selective KMO inhibitor does not significantly modify behavioral phenotypes or natural progression in mouse models of HD."( The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
Beaumont, V; Bradaia, A; Deisemann, H; Dijkman, U; Dominguez, C; Ebneth, A; Freije, R; Gelman, S; Gleyzes, M; Heikkinen, T; Heins, M; Javier, RM; Khetarpal, V; Kontkanen, O; Lehtimäki, K; Mrzljak, L; Munoz-Sanjuan, I; Neagoe, I; Park, LC; Puoliväli, J; Rassoulpour, A; Steidl, E; Toledo-Sherman, L; Tombaugh, G; Winkler, D, 2016
)
0.43
" Baicalein (BC), scientifically 5,6,7 trihydroxy flavone present naturally in the edible plants like Scutellaria baicalensis and Oroxylum indicum possess a better neuroprotective effect in the dosage of 10 mg/kg and 30 mg/kg intraperitoneally in the striatum of HD induced rats."( 5,6,7 trihydroxy flavone armoured neurodegeneration caused by Quinolinic acid induced huntington's like disease in rat striatum - reinstating the level of brain neurotrophins with special reference to cognitive-socio behaviour, biochemical and histopathol
Purushothaman, B; Sumathi, T, 2022
)
0.96
" We need to pay attention to the dosage of ceftazidime and to the appearance of neurological symptoms."( Ceftazidime encephalopathy developed without the elevation of cerebrospinal fluid concentration of ceftazidime: A case report of two cases.
Fujii, K; Hasegawa, N; Hosoya, K; Kato, A; Kobayashi, E; Komatsu, M; Matsumoto, K; Ryuzaki, M; Taguchi, K; Toda, M; Yoshifuji, A, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
NMDA receptor agonistAn excitatory amino acid agonist which binds to NMDA receptors and triggers a response.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyridinedicarboxylic acidAny member of the class of pyridines carrying two carboxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (16)

PathwayProteinsCompounds
Nicotinate and Nicotinamide Metabolism1434
Tryptophan Metabolism1855
NAD Biosynthesis520
NAD Metabolism1435
Nicotinate and Nicotinamide metabolism ( Nicotinate and Nicotinamide metabolism )2225
Tryptophan degradation ( Tryptophan degradation )6454
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
Kynurenine pathway and links to cell senescence2024
tryptophan degradation via kynurenine016
NAD biosynthesis (from tryptophan)020
NAD biosynthesis I from aspartate020
NAD biosynthesis II from tryptophan024
Selenium micronutrient network095
NAD biosynthesis II (from tryptophan)024
Biochemical pathways: part I0466
NAD+ biosynthetic pathways014

Protein Targets (56)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency84.36790.003245.467312,589.2998AID2517
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency8.22050.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency0.89130.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency1.55500.177814.390939.8107AID2147
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.38140.100020.879379.4328AID588453; AID588456
15-lipoxygenase, partialHomo sapiens (human)Potency39.81070.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency89.12510.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency0.08410.000811.382244.6684AID686978
Microtubule-associated protein tauHomo sapiens (human)Potency6.12780.180013.557439.8107AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency14.98890.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency5.01190.001318.074339.8107AID926; AID938
regulator of G-protein signaling 4Homo sapiens (human)Potency9.46620.531815.435837.6858AID504845
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency6.30960.707936.904389.1251AID504333
arylsulfatase AHomo sapiens (human)Potency0.84921.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency8.36190.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency100.00000.540617.639296.1227AID2364; AID2528
runt-related transcription factor 1 isoform AML1bHomo sapiens (human)Potency24.80330.02007.985839.8107AID504374; AID504375
chromobox protein homolog 1Homo sapiens (human)Potency2.81840.006026.168889.1251AID488953
core-binding factor subunit beta isoform 2Homo sapiens (human)Potency24.80330.02007.985839.8107AID504374; AID504375
flap endonuclease 1Homo sapiens (human)Potency46.93470.133725.412989.1251AID588795
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency39.81070.050127.073689.1251AID588590
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency22.38720.075215.225339.8107AID485360
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency1.58490.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
neuropeptide S receptor isoform AHomo sapiens (human)Potency1.00000.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysine-specific demethylase 4EHomo sapiens (human)IC50 (µMol)5,000.00000.20001.95696.3096AID1798635
Glutamate receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00011.617910.0000AID31587
Glutamate receptor 2Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00011.700010.0000AID31587
Glutamate receptor 3Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00011.700010.0000AID31587
Glutamate receptor 4Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00011.700010.0000AID31587
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00071.600310.0000AID144992
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00071.630610.0000AID144992
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00061.525710.0000AID144992
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00071.747210.0000AID144992
Beta-lactamase Aeromonas hydrophilaKi200.00004.50005.10005.7000AID323626
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00071.741110.0000AID144992
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00071.741110.0000AID144992
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)100.00000.00071.741110.0000AID144992
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Advanced glycosylation end product-specific receptorHomo sapiens (human)Kd0.04300.03000.03650.0430AID1475140
Advanced glycosylation end product-specific receptorRattus norvegicus (Norway rat)Kd0.04300.04300.04300.0430AID1475139
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (48)

Processvia Protein(s)Taxonomy
regulation of gene expressionLysine-specific demethylase 4EHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 4EHomo sapiens (human)
response to hypoxiaAdvanced glycosylation end product-specific receptorHomo sapiens (human)
microglial cell activationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of T cell mediated cytotoxicityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of protein phosphorylationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
inflammatory responseAdvanced glycosylation end product-specific receptorHomo sapiens (human)
cell adhesionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
cell surface receptor signaling pathwayAdvanced glycosylation end product-specific receptorHomo sapiens (human)
learning or memoryAdvanced glycosylation end product-specific receptorHomo sapiens (human)
response to woundingAdvanced glycosylation end product-specific receptorHomo sapiens (human)
glucose mediated signaling pathwayAdvanced glycosylation end product-specific receptorHomo sapiens (human)
neuron projection developmentAdvanced glycosylation end product-specific receptorHomo sapiens (human)
negative regulation of interleukin-10 productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of chemokine productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of interleukin-1 beta productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of interleukin-12 productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of interleukin-6 productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of tumor necrosis factor productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of heterotypic cell-cell adhesionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of activated T cell proliferationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
transcytosisAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of JNK cascadeAdvanced glycosylation end product-specific receptorHomo sapiens (human)
astrocyte activationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of synaptic plasticityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
induction of positive chemotaxisAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of monocyte chemotactic protein-1 productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
protein localization to membraneAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of spontaneous synaptic transmissionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
transport across blood-brain barrierAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of long-term synaptic potentiationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
negative regulation of long-term synaptic potentiationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
negative regulation of long-term synaptic depressionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of p38MAPK cascadeAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of non-canonical NF-kappaB signal transductionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic processAdvanced glycosylation end product-specific receptorHomo sapiens (human)
negative regulation of blood circulationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of endothelin productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
response to amyloid-betaAdvanced glycosylation end product-specific receptorHomo sapiens (human)
cellular response to amyloid-betaAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of monocyte extravasationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of CD4-positive, alpha-beta T cell activationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of dendritic cell differentiationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of inflammatory responseAdvanced glycosylation end product-specific receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
metal ion bindingLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
amyloid-beta bindingAdvanced glycosylation end product-specific receptorHomo sapiens (human)
transmembrane signaling receptor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
scavenger receptor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
protein bindingAdvanced glycosylation end product-specific receptorHomo sapiens (human)
signaling receptor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
identical protein bindingAdvanced glycosylation end product-specific receptorHomo sapiens (human)
S100 protein bindingAdvanced glycosylation end product-specific receptorHomo sapiens (human)
protein-containing complex bindingAdvanced glycosylation end product-specific receptorHomo sapiens (human)
advanced glycation end-product receptor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
molecular adaptor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
laminin receptor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
nucleusLysine-specific demethylase 4EHomo sapiens (human)
nucleoplasmLysine-specific demethylase 4EHomo sapiens (human)
chromatinLysine-specific demethylase 4EHomo sapiens (human)
nucleusLysine-specific demethylase 4EHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
fibrillar centerAdvanced glycosylation end product-specific receptorHomo sapiens (human)
extracellular regionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
plasma membraneAdvanced glycosylation end product-specific receptorHomo sapiens (human)
cell surfaceAdvanced glycosylation end product-specific receptorHomo sapiens (human)
apical plasma membraneAdvanced glycosylation end product-specific receptorHomo sapiens (human)
cell junctionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
postsynapseAdvanced glycosylation end product-specific receptorHomo sapiens (human)
plasma membraneAdvanced glycosylation end product-specific receptorHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (78)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID143257pKa was determined1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Synthesis and structure-activity studies on acidic amino acids and related diacids as NMDA receptor ligands.
AID1475139Binding affinity to Wistar rat His-tagged RAGE domain VC1 expressed in Escherichia coli by fluorescence titration method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective.
AID323615Inhibition of Bacillus cereus metallo beta lactamase Bc2 assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID323619Inhibition of Stenotrophomonas maltophilia metallo beta lactamase L1 assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID385998Inhibition of IL13 production in transgenic BALB/c mouse TH2 cells at 500 uM after 48 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis.
AID31587Tested in vitro for the concentration required to inhibit [3H]AMPA radioligand at EAA receptor sites in rat cortical membranes1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Synthesis and structure-activity studies on acidic amino acids and related diacids as NMDA receptor ligands.
AID386215Antiasthmatic effect in ovalbumin-challenged BALB/c mouse assessed as decrease in IL5 level in bronchoalveolar lavage fluid by ELISA2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID386002Inhibition of IL10 production in transgenic BALB/c mouse TH2 cells at 500 uM after 48 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID385990Inhibition of IL4 production in transgenic BALB/c mouse TH2 cells at 500 uM after 48 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis.
AID144827Tested in vitro for the concentration required to inhibit [3H]MK-801 radioligand at EAA receptor sites in rat cortical membranes; not tested1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Synthesis and structure-activity studies on acidic amino acids and related diacids as NMDA receptor ligands.
AID323613Inhibition of Pseudomonas aeruginosa 101/1477 metallo beta lactamase IMP1 expressed in in Escherichia coli assessed as residual enzyme activity at 100 uM in absence of zinc2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID323620Inhibition of Legionella gormani beta lactamase metallo FEZ1 expressed in Escherichia coli assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID1475140Binding affinity to human His-tagged RAGE domain VC1 expressed in Escherichia coli by fluorescence titration method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective.
AID175684Effective concentration in vitro as electropharmacological activity in the rat cortical wedge preparation1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Synthesis and structure-activity studies on acidic amino acids and related diacids as NMDA receptor ligands.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID386214Antiasthmatic effect in ovalbumin-challenged BALB/c mouse assessed as decrease in eosinophil infiltration in bronchoalveolar lavage fluid2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis.
AID144611Compound was evaluated for its ability to displace [3H]Glu/[3H]-AP5 from rat brain membrane1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Generation of N-methyl-D-aspartate agonist and competitive antagonist pharmacophore models. Design and synthesis of phosphonoalkyl-substituted tetrahydroisoquinolines as novel antagonists.
AID323626Inhibition of Aeromonas hydrophila beta lactamase CphA by competitive inhibition assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID344916Inhibition of 2-oxoglutarate-dependent human JMJD2E in presence of excess 2-oxoglutarate and 10 uM Fe2 by FDH coupled assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID386216Antiasthmatic effect in ovalbumin-challenged BALB/c mouse assessed as decrease in IL13 level in bronchoalveolar lavage fluid by ELISA2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis.
AID323616Inhibition of metallo beta lactamase VIM2 assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID180057Neuroprotective effect evaluated for excitatory amino acid receptor antagonism with the concentration at 1 uL in the corpus striatum of 14 rats with glutamic acid decarboxylase as the marker enzyme.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Novel class of amino acid antagonists at non-N-methyl-D-aspartic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology, and neuroprotection.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID385994Inhibition of IL5 production in transgenic BALB/c mouse TH2 cells at 500 uM after 48 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis.
AID144992Tested in vitro for the concentration required to inhibit [3H]CPP radioligand at EAA receptor sites in rat cortical membranes1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Synthesis and structure-activity studies on acidic amino acids and related diacids as NMDA receptor ligands.
AID323617Inhibition of metallo beta lactamase VIM4 assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID323618Inhibition of Aeromonas hydrophila metallo beta lactamase CphA assessed as residual enzyme activity at 100 uM in absence of zinc2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID323627Inhibition of Aeromonas hydrophila beta lactamase CphA N116H-N220G mutant by competitive inhibition assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID180056Neuroprotective effect evaluated for excitatory amino acid receptor antagonism with the concentration at 1 uL in the corpus striatum of 14 rats with choline acetyltransferase as the marker enzyme.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Novel class of amino acid antagonists at non-N-methyl-D-aspartic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology, and neuroprotection.
AID323614Inhibition of Pseudomonas aeruginosa 101/1477 metallo beta lactamase IMP1 expressed in in Escherichia coli assessed as residual enzyme activity at 100 uM in presence of zinc chloride2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID344917Inhibition of 2-oxoglutarate-dependent human JMJD2E in presence of excess H3K9me3 peptide and 10 uM Fe2 by FDH coupled assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1798635FDH Coupled Inhibition Assay from Article 10.1021/jm800936s: \\Inhibitor Scaffolds for 2-Oxoglutarate-Dependent Histone Lysine Demethylases.\\2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,788)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990216 (12.08)18.7374
1990's587 (32.83)18.2507
2000's468 (26.17)29.6817
2010's380 (21.25)24.3611
2020's137 (7.66)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.02 (24.57)
Research Supply Index7.54 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index80.83 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (49.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials19 (1.02%)5.53%
Reviews101 (5.44%)6.00%
Case Studies6 (0.32%)4.05%
Observational3 (0.16%)0.25%
Other1,727 (93.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]